CN101164593A - Oral liquid for treating kidney disease - Google Patents
Oral liquid for treating kidney disease Download PDFInfo
- Publication number
- CN101164593A CN101164593A CNA2006100480339A CN200610048033A CN101164593A CN 101164593 A CN101164593 A CN 101164593A CN A2006100480339 A CNA2006100480339 A CN A2006100480339A CN 200610048033 A CN200610048033 A CN 200610048033A CN 101164593 A CN101164593 A CN 101164593A
- Authority
- CN
- China
- Prior art keywords
- grams
- radix
- treatment
- rhizoma
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a Chinese medicine oral liquor for curing nephroses with obvious therapeutic effect and high cure rate. Said Chinese medicine oral liquor is made up by using 22 Chinese medicinal materials of coptis root, scutellaria root, astragalus root, phellodendron bark, rhubarb, cooked rehmannia root and others through a certain preparation process.
Description
[technical field]
The present invention relates to a kind of Chinese medicine oral liquid for the treatment of nephropathy.
[background technology]
Present general many hormone medicines of use of treatment nephropathy, as " prednisone " etc., shortcoming is a weak curative effect, and cure rate is low, and takes inducing neural symptom and digestive system and ulcer, osteoporosis for a long time, and growth promoter is suppressed, and is concurrent and increase the weight of infection etc.
[summary of the invention]
The purpose of this invention is to provide a kind of oral liquid for the treatment of nephropathy, its good effect, the cure rate height, and have no side effect.
The object of the present invention is achieved like this: get Chinese medicine Rhizoma Coptidis 5 gram, Radix Scutellariae 12 grams, the Radix Astragali 35 grams, Cortex Phellodendri 10 grams, Radix Et Rhizoma Rhei 5 grams, Radix Rehmanniae Preparata 13 grams, the Cortex Eucommiae 12 grams, Fructus Forsythiae 15 grams, Herba Andrographis 8 grams, Folium Isatidis 13 grams, Herba Scutellariae Barbatae 18 grams, Ramulus Cinnamomi 10 grams, Herba Houttuyniae 18 grams, Fructus Lycii 10 grams, Radix Ophiopogonis 8 grams, the Radix Paeoniae Alba 12 grams, the Rhizoma Atractylodis Macrocephalae 12 grams, Rhizoma Alismatis 9 grams, Poria 15 grams, Semen Plantaginis 15 grams, Herba Lysimachiae 18 grams, Rhizoma Imperatae 15 grams and mix decoctings, each surplus medicinal liquid 40 grams, fry in shallow oil altogether 3 times, count to such an extent that medicinal liquid 120 restrains, the bottling sealing.
[specific embodiment]
Get Chinese medicine Rhizoma Coptidis 5 gram, Radix Scutellariae 12 grams, the Radix Astragali 35 grams, Cortex Phellodendri 10 grams, Radix Et Rhizoma Rhei 5 grams, Radix Rehmanniae Preparata 13 grams, the Cortex Eucommiae 12 grams, Fructus Forsythiae 15 grams, Herba Andrographis 8 grams, Folium Isatidis 13 grams, Herba Scutellariae Barbatae 18 grams, Ramulus Cinnamomi 10 grams, Herba Houttuyniae 18 grams, Fructus Lycii 10 grams, Radix Ophiopogonis 8 grams, the Radix Paeoniae Alba 12 grams, the Rhizoma Atractylodis Macrocephalae 12 grams, Rhizoma Alismatis 9 grams, Poria 15 grams, Semen Plantaginis 15 grams, Herba Lysimachiae 18 grams, Rhizoma Imperatae 15 grams and mix decoctings, each surplus medicinal liquid 40 grams, fry in shallow oil altogether 3 times, count to such an extent that medicinal liquid 120 restrains, the bottling sealing.
Usage and dosage: become each 40 grams of human oral, every day 2 times, 10 days one courses of treatment.
Advantage of the present invention is: the deficiency of both QI and blood that the treatment of medicines such as Radix Ophiopogonis, Radix Rehmanniae Preparata, the Rhizoma Atractylodis Macrocephalae causes owing to the nephrotic syndrome, deficiency of both YIN and YANG; Medicine such as Rhizoma Alismatis, Poria is a damp-clearing drug, diseases such as treatment edema; The evil poison invasion of other internal organs that clearing away heat-damp and expelling toxic material such as Cortex Phellodendri, Fructus Forsythiae medicine treatment kidney disease and nephropathy are caused also has effects such as lowering creatinine, blood urea nitrogen, and to various nephritis, nephrotic syndrome good effect, the cure rate height is difficult for recurrence, has no side effect.
Details are as follows to contrast situation the course of treatment with the curative effect of the present invention's " a kind of oral liquid for the treatment of nephropathy " and " prednisone " treatment nephropathy:
One, case selection: the diagnosis basis according to the nephrotic syndrome is selected case, age, sex, occupation is not limit, discharge renal calculus, tumor of kidney, middle and advanced stage uremia, treat 116 examples (the various nephritis and the various nephrotic syndrome being divided into nephritis and the nephrotic syndrome two big classes) altogether in order to exemplify, nephritis 44 examples, the nephrotic syndrome 72 examples, wherein male 64 examples, woman's 52 examples, the oldest 72 years old, minimum 14 years old, diagnostic criteria: edema, hematuria, a large amount of albuminuria, hypertension, hypercholesterolemia, lasting disease time such as hypoproteinemia from some months to more than several years.
Two, efficacy assessment standard: evaluate by the healing improvement standard in " clinical disease diagnosis foundation, cures transfer standard to ", cure: symptom control, observe not have more than a year and recur; Take a turn for the better: sx, the acute attack number of times reduces (the big volume of the 4th army of the Chinese People's Liberation Army, front page); Invalid: according to the clinical practice situation, after the patient took medicine ten days, symptom did not see and alleviates that refusal continues to take this medicine, thinks invalid.
Three, for observe the curative effect, the nephrotic is divided into two groups of nephritis and the nephrotic syndromes, and the relation of the record course of disease, the course of treatment, age and curative effect, set up matched group to compare, the patient selection of matched group is identical with the treatment group or close as far as possible, matched group 116 examples, nephritis 46 examples, the nephrotic syndrome 70 examples, wherein male 65 examples, women 51 examples, the oldest 70 years old, minimum 16 years old, the treatment group was with the present invention " a kind of oral liquid for the treatment of nephropathy ", the medicine that matched group is selected for use is " prednisone " sheet, takes (be about 12 general every day) by physician guidance.Details as Follows:
Case and curative effect statistical table ()
From the table (one) as can be seen: treatment group and matched group are all higher to the curative effect of two types, and the treatment group is higher than matched group again, P≤0.01, difference has the highly significant meaning.From the effective percentage situation, the treatment group also is higher than matched group, P≤0.05, difference significance.
The course of disease and curative effect statistical table (two)
From table (two) as can be seen: treatment group and matched group are to the treatment of the nephropathy prolongation with the course of disease, and curative effect reduces gradually, and the treatment group is compared with matched group, and cure rate, effective percentage are all apparently higher than matched group.[illustrating: effective percentage=(healing+improvement) ÷ example number * %].
The course of treatment and curative effect statistical table (three)
Annotate: 10 is a course of treatment.
From table (three) as can be seen, treatment group and matched group to the patient through the treatment of 1-2 the course of treatment, healing person not, the effective percentage of treatment group is apparently higher than matched group.Along with the prolongation of the course of treatment, cure rate increases gradually, and the course of treatment is long more, and cure rate is high more, and the treatment group is significantly higher than matched group.
Age and curative effect statistical table (four)
As can be seen, the age does not have much influences to effective percentage and cure rate from table (four)
By the comparison of above-mentioned treatment group and matched group, " a kind of oral liquid for the treatment of nephropathy " effect of producing in clinical practice has certain enthusiasm as can be seen.
Claims (1)
1. oral liquid for the treatment of nephropathy is characterized in that being made by following weight proportion by following medicine: Rhizoma Coptidis 5 grams, Radix Scutellariae 12 grams, the Radix Astragali 35 grams, Cortex Phellodendri 10 grams, Radix Et Rhizoma Rhei 5 grams, Radix Rehmanniae Preparata 13 grams, the Cortex Eucommiae 12 grams, Fructus Forsythiae 15 grams, Herba Andrographis 8 grams, Folium Isatidis 13 grams, Herba Scutellariae Barbatae 18 grams, Ramulus Cinnamomi 10 grams, Herba Houttuyniae 18 grams, Fructus Lycii 10 grams, Radix Ophiopogonis 8 grams, the Radix Paeoniae Alba 12 grams, the Rhizoma Atractylodis Macrocephalae 12 grams, Rhizoma Alismatis 9 grams, Poria 15 grams, Semen Plantaginis 15 grams, Herba Lysimachiae 18 grams, Rhizoma Imperatae 15 grams.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100480339A CN100548354C (en) | 2006-10-17 | 2006-10-17 | A kind of oral liquid for the treatment of nephropathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100480339A CN100548354C (en) | 2006-10-17 | 2006-10-17 | A kind of oral liquid for the treatment of nephropathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101164593A true CN101164593A (en) | 2008-04-23 |
| CN100548354C CN100548354C (en) | 2009-10-14 |
Family
ID=39333547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100480339A Expired - Fee Related CN100548354C (en) | 2006-10-17 | 2006-10-17 | A kind of oral liquid for the treatment of nephropathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100548354C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102614423A (en) * | 2012-04-09 | 2012-08-01 | 李香云 | Traditional Chinese medical decoction for treatment of chronic kidney disease |
| CN103028056A (en) * | 2012-12-04 | 2013-04-10 | 肖毅峰 | Frequently-drank tea-substituting traditional Chinese medicine preparation for treating kidney diseases |
| CN103705825A (en) * | 2013-12-30 | 2014-04-09 | 孙亚平 | Application of lespedeza cuneata turbidity removing tablet in preparation of medicine for inhibiting cell proliferation of embryonal carcinoma F9 |
| CN103893592A (en) * | 2014-03-26 | 2014-07-02 | 叶葵 | Traditional Chinese medicine for treating nephrotic syndrome |
| CN104771607A (en) * | 2015-01-27 | 2015-07-15 | 刘卓韬 | Traditional Chinese medicinal composition and acupoint combination acupuncture application for treating nephritis |
| CN105521039A (en) * | 2014-09-28 | 2016-04-27 | 陆永达 | Oral nephritis treating traditional Chinese medicine liquid |
| CN107362306A (en) * | 2017-06-28 | 2017-11-21 | 禹州市合同泰药业有限公司 | A kind of Chinese medicine composition of depressor muscle acid anhydride and preparation method thereof |
-
2006
- 2006-10-17 CN CNB2006100480339A patent/CN100548354C/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102614423A (en) * | 2012-04-09 | 2012-08-01 | 李香云 | Traditional Chinese medical decoction for treatment of chronic kidney disease |
| CN102614423B (en) * | 2012-04-09 | 2013-06-12 | 李香云 | Traditional Chinese medical decoction for treatment of chronic kidney disease |
| CN103028056A (en) * | 2012-12-04 | 2013-04-10 | 肖毅峰 | Frequently-drank tea-substituting traditional Chinese medicine preparation for treating kidney diseases |
| CN103705825A (en) * | 2013-12-30 | 2014-04-09 | 孙亚平 | Application of lespedeza cuneata turbidity removing tablet in preparation of medicine for inhibiting cell proliferation of embryonal carcinoma F9 |
| CN103705825B (en) * | 2013-12-30 | 2016-01-20 | 滨州市人民医院 | Pure and impure of ferrum broom suppresses the application in teratocarcinoma cell F9 cell proliferation in preparation |
| CN103893592A (en) * | 2014-03-26 | 2014-07-02 | 叶葵 | Traditional Chinese medicine for treating nephrotic syndrome |
| CN105521039A (en) * | 2014-09-28 | 2016-04-27 | 陆永达 | Oral nephritis treating traditional Chinese medicine liquid |
| CN104771607A (en) * | 2015-01-27 | 2015-07-15 | 刘卓韬 | Traditional Chinese medicinal composition and acupoint combination acupuncture application for treating nephritis |
| CN107362306A (en) * | 2017-06-28 | 2017-11-21 | 禹州市合同泰药业有限公司 | A kind of Chinese medicine composition of depressor muscle acid anhydride and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100548354C (en) | 2009-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1919330A (en) | Traditional medicine composition for treating chronic colitis and its preparing process | |
| CN100548354C (en) | A kind of oral liquid for the treatment of nephropathy | |
| CN101485803B (en) | Chinese medicinal composition for treating menoxenia and dysmenorrhea | |
| CN102552761A (en) | Chinese medicinal pills for treating psoriasis | |
| CN1152707C (en) | pill for treating diarrhea | |
| CN1060391C (en) | Traditional Chinese medicine for treating gynecological tumour | |
| CN101002848B (en) | Medicine for treating recurrent uarthritis, and its preparing method | |
| CN101130052A (en) | Traditional Chinese medicine for treating postpartum arthralgia | |
| CN1111046C (en) | Chinese medicine preparation for curing postpartum disease of woman | |
| CN1137404A (en) | Drug for curing pulmonary tuberculosis | |
| CN1351872A (en) | Chinese herbal medicine for curing comedo and acne | |
| CN1067571C (en) | Chinese medicine capsule for treating lumbar and cervical protrusion | |
| CN1481870A (en) | Compound traditional Chinese medicine preparation for treating intractable chronic constipation and preparation method thereof | |
| CN1253196C (en) | Medicine for treating colitis | |
| CN1199679C (en) | Medicine for nourishing yin and fortifying kidney, benefiting qi and fortifying spleen , and its preparation method | |
| CN103550668B (en) | A kind of Chinese medicine for the treatment of gynecological's habitual abortion disease | |
| CN1260209A (en) | Medicine for nephritis | |
| CN101961455A (en) | Traditional Chinese medicine for treating chronic colitis disease | |
| CN101485823B (en) | Medicament for treating lung cancer and preparation method thereof | |
| CN101152380A (en) | Traditional Chinese medicine for treating early postoperative inflammatory ileus | |
| CN1265818C (en) | Leech capsule | |
| CN111388543A (en) | Traditional Chinese medicine composition for treating gout and preparation and application thereof | |
| CN1279953C (en) | Mediciation for curing female disease | |
| CN102366594A (en) | Traditional Chinese medicine for adjusting menstruation | |
| CN103349767B (en) | Inula nervosa Wall oil capsule preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091014 Termination date: 20121017 |